These findings unveil EGLN1 as a novel regulator of myocardial angiogenesis in DCM, proposing autophagy activation as a potential therapeutic strategy to ameliorate diabetic cardiovascular complications. This evidence concerns the gene EGLN1 and familial dilated cardiomyopathy.